



**Food and Agriculture
Organization of the
United Nations**



**World Health
Organization**

JOINT FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES

Expert meeting of Working Group established to

consider the evaluation of enzyme preparations

used in the manufacture of foods

Rome, 11-14 December 2018

FINAL REPORT

Issued November 2019

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

**Evaluation of enzyme preparations used in
the manufacture of foods**

Food and Agriculture Organization of the United Nations
World Health Organization
Rome, 2019

51	Table of Contents	
52	1. Background	5
53	2. Draft changes to chapter 9.1.4.2 EHC 240 from the JECFA working group	
54	on enzymes	7
55	3. List of recommendations for adoption by JECFA	20
56	4. List of abbreviations	22
57	<i>Annex 1.</i> Draft report on enzyme assessment for JECFA food additives	23
58	<i>Annex 2.</i> Definitions for safe food enzyme production strain and presumed safe	
59	progeny strain	42
60	<i>Annex 3.</i> Information required for the safety assessment of enzyme preparation	
61	for use in foods	43
62	<i>Annex 4.</i> Terms and definitions	50
63	<i>Annex 5.</i> List of experts	51
64		

65 1. Background

66
67 The Working Group (WG) met to discuss recent advances in the understanding of the
68 safety of enzyme preparations for use in food and the need to revise Chapter 9.1.4.2 of
69 *Principles and methods for the risk assessment of chemicals in food; Environmental Health*
70 *Criteria* 240¹, (EHC 240). The WG also discussed the possibility of reducing the extent of
71 toxicological testing necessary for enzyme preparations derived from well characterized
72 micro-organisms and how this should be reflected in Chapter 9.1.4.2. Since the publication
73 of the JECFA guidance on the evaluation of enzymes for use in foods in 2006, there has been
74 a steady increase in the number of enzymes from genetically engineered microbial sources.
75 In the guidance, JECFA had previously acknowledged the possibility of toxin production and
76 the generation of an allergenic protein, among other potential issues. This Working Group
77 identified ways to approach these aspects in the evaluation process and proposed revisions
78 to the guidance in EHC 240, Chapter 9.1.4.2 pertaining to enzyme preparations for use in
79 food. The Working Group also recognised that these revisions would need to be reflected in
80 the “*Combined Compendium of Food Additive Specifications. Volume 4 – Analytical methods,*
81 *test procedures and laboratory solutions used by and referenced in the food additive*
82 *specifications.*”

83 At the time of the meeting, the Codex Committee on Food Additives (CCFA) *Priority list of*
84 *substances proposed for evaluation by JECFA* contained 29 enzyme preparations produced by
85 microorganisms (REP18/FA Appendix X²). To assist in addressing these requests, the
86 Working Group considered the current safety evaluation process for enzyme preparations
87 for use in foods and the state of the art of food enzyme production. To lead into the
88 discussions, the Working Group considered a background document (*Annex 1*) presenting
89 newer approaches in the consideration of enzyme safety since the last revision was made in
90 2006. The factors presented in Table 1 framed the deliberations of the Working Group.

¹ EHC 240 (2009) Principles and methods for the risk assessment of chemicals in food; Environmental Health Criteria 240, Food and Agricultural Organization of the United Nations and the World Health Organization. [Inchem.org/documents/ehc/ehc/ehc240_index.htm](http://www.inchem.org/documents/ehc/ehc/ehc240_index.htm)

² http://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FMeetings%252FCX-711-50%252FReport%252FREP18_FAE.pdf

91 **Table 1: Factors considered by the experts for the revision of the safety evaluation of**
 92 **enzyme preparations for use in foods**

Factors	Elements
History of safe use of the production micro-organism	Genetic stability/instability of a given construct Toxigenicity and pathogenicity Safety data from production strains of the same lineage
Enzyme preparations from the same source organism	Strain performance/productivity Enzyme activity and TOS Whole genome sequence Identification of the specific modification
GMP production	Control of toxin production Carryover of residual components in the growth medium from manufacturing Enzyme purity in TOS
Presence or absence of production strain in final product	Carryover of secondary metabolites
Dietary exposure	Levels of use in food production and in the final food
<i>In silico</i> database comparisons	Prediction of similarity with known allergens Prediction of protein toxicity
Digestibility	Determination of <i>in vitro</i> digestibility to assess absence of allergenic protein fragments

93 These discussions led to the a proposal for revision of Chapter 9.1.4.2 in EHC 240,
 94 including revision to the classification of enzymes (Section 2, below); a list of
 95 Recommendations for adoption by JECFA, below (Section 3, below); the development of
 96 definitions for “Safe Food Enzyme Production Strain” and “Presumed Safe Progeny Strain”
 97 for use by JECFA (*Annex 2*); a checklist of information required for the safety evaluation of
 98 enzyme preparations for use in foods (*Annex 3*); and list of terms and definitions related to
 99 the safety evaluation of enzyme preparations for use in food (*Annex 4*).

100 **2. Draft Changes to Chapter 9.1.4.2 EHC 240 proposed by the JECFA Working Group on**
101 **Enzymes**
102

103 The history of enzyme use in food applications is long and well known, especially in
104 bread-, cheese-, wine-, and beer-making where enzymes are part of the processing or
105 maturation processes. Enzymes used in the food industry are derived from animal tissues,
106 plants and microorganisms. However, most commercial enzymes are produced from
107 microorganisms that are enhanced through natural selection, classical strain improvement
108 techniques (e.g. mutagenesis and selection), recombinant-DNA technologies and gene
109 editing. Microbial enzymes are typically produced by controlled fermentation followed by
110 removal of the production microorganism, purification and concentration of the enzyme.
111 Final standardization with stabilizers, preservatives, carriers, diluents, and other approved
112 food-grade additives and ingredients is carried out after the purification and concentration
113 steps. The formulated enzymes are referred to as enzyme preparations, which, depending
114 upon the application, may be produced as a liquid, semi-liquid or dried product. Enzyme
115 preparations may contain either one major active enzyme that catalyzes a specific reaction
116 during food processing or two or more active enzymes that catalyze different reactions.

117 Enzyme preparations often contain organic constituents of the production organism
118 and compounds carried over from the manufacturing process — for example, the residues
119 of the fermentation broth. In 2006, the sixty-fifth JECFA Committee elaborated principles
120 and procedures for the safety assessment of enzyme preparations for use in food whereby,
121 an enzyme preparation must comply with the *General Specifications and Considerations for*
122 *Enzyme Preparations Used in Food Processing* (FAO, 2006a; FAO, 2006b). The documents
123 addressed certain aspects that apply to the safety evaluation of all enzyme preparations,
124 including the safety evaluation of the production organism, the enzyme component, side
125 activities, the manufacturing process and the consideration of dietary exposure.

126

127 Some of the specific safety concerns are:

128 *1. Potential for the enzyme to cause an allergic reaction*

129 *1.1 Food allergies*

130 Food allergies are adverse immunological reactions to an otherwise harmless
131 food, such as a protein. The severity of food allergies in susceptible individuals
132 (atopy) can range from mild to severe, and in some cases can be life-threatening. The
133 most common type of food allergy is mediated by allergen specific immunoglobulin E
134 (IgE) antibodies. Allergens are almost always proteins (e.g. Ara h2 in peanuts, papain
135 in papaya, lacto-peroxidase in cow's milk), but not all food proteins are allergens. As
136 there is no single test that can accurately predict whether a microbially synthesized
137 enzyme will immunologically cross-react with an established allergen, a Weight-of-
138 Evidence approach should be used (FAO/WHO, 2001). One approach that has
139 routinely been used by JECFA is to compare the amino acid sequence of an enzyme
140 against known linear IgE-binding epitopes in allergenic proteins using *in silico*
141 methods and appropriate protein databases [e.g. Food Allergy Research and Resource
142 Program, University of Nebraska; AllergenOnline (<http://www.allergenonline.org>)].
143 The possibility of immunological cross-reactivity between the expressed enzyme and
144 a known allergen is considered when there is:

- 145
- 146 a. at least 35% identity in the amino acid sequence of the expressed protein (i.e.
147 without the leader sequence, if any), using a sliding window of 80 amino acids
148 and a suitable gap penalty (for algorithms such as FASTA or BLASTP (Codex
149 Alimentarius, 2003), or equivalent);
 - 150
 - 151 b. identification of eight contiguous amino acids common to the expressed
152 enzyme and a known allergen (JECFA, 2016).

153

154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183

1.2 Allergenic food proteins and resistance to proteolysis

The susceptibility of a dietary protein to proteolytic degradation by digestive enzymes, such as gastric pepsin, could potentially provide information on its immunological safety for human consumption. While most dietary proteins are readily hydrolysed to peptides and amino acids in the gastrointestinal tract, there is evidence that many potent food allergens are resistant to proteolysis (Schmidt *et al.*, 1995; FAO/WHO, 2001; Bannon, 2004; Moreno *et al.*, 2005). *In vitro* pepsinolysis assays (Thomas, *et al.*, 2004) have been proposed as an additional piece of information as part of a Weight-of-Evidence approach for newly expressed proteins (Codex Alimentarius, 2009). A pepsinolysis assay that is based on simulated gastric fluid (SGF) and usually used in pre-clinical testing of pharmaceuticals, has been described by the United States Pharmacopeia (2000). The SGF is often used to allow comparisons between different newly-expressed proteins under experimental conditions (Astwood *et al.*, 1999). However, to date, such pepsin resistance data for enzymes have rarely been submitted to JECFA for consideration within a Weight-of-Evidence approach. This may be because there are studies, albeit not using the same pH, purity and activity of pepsin and pepsin-to-substrate protein ratio, which have shown that the correlation with allergenic potential is not absolute and that proteins which are resistant to pepsinolysis might not be allergenic under physiological conditions of dietary exposure whereas labile proteins (eg. β -casein) or peptides formed during proteolysis may be allergenic (Vieths *et al.*, 1999; Yagami *et al.*, 2000; Wal, 2001; Fu *et al.*, 2002; Bøgh & Madsen, 2015). Consequently, data on resistance to pepsinolysis from *in vitro* tests are currently not considered to be strong evidence for the absence of intrinsic allergenicity of a protein, but still may have some utility as part of a Weight-of-Evidence approach.

1.3 Occupational hazards – respiratory allergies, skin and eye irritation

A known safety risk linked to industrial enzyme use is respiratory allergy and for most proteases there is also some potential for skin and eye irritation

184 (Vanhanen, 2001; Anderson *et al.*, 2017). Enzymes present a risk of a respiratory
185 allergy (e.g. Aspergillus-derived enzymes in bakers' asthma) and it is well
186 described in the scientific literature (Quirce *et al.*, 1992; Green & Beezhold, 2001).
187

188 1. *Safety concerns pertaining to enzyme preparations derived from genetically modified*
189 *microorganisms.*

190 The *General Specifications and Considerations for Enzyme Preparations Used in*
191 *Food Processing* (2006) provides recommendations on the safety assessment of the
192 genetic material inserted into the genome of the production microorganism. Two
193 additional considerations that were introduced in the 2006 revision of the document
194 state:

- 195
- 196 a. For enzyme preparations from recombinant-DNA-modified microorganisms
197 the genetic material introduced into and remaining in the production
198 microorganism should be characterized and evaluated for function and safety,
199 including evidence that it does not contain genes encoding known virulence
200 factors, protein toxins, and enzymes involved in the synthesis of mycotoxins
201 or other toxic or undesirable substances.
202
 - 203 b. Recombinant-DNA-modified production microorganisms might contain genes
204 encoding proteins that inactivate clinically useful antibiotics. Enzyme
205 preparations derived from such microorganisms should contain neither
206 antibiotic inactivating proteins at concentrations that would interfere with
207 antibiotic treatment nor transformable DNA that could potentially contribute
208 to the spread of antibiotic resistance.

209

210 It must be pointed out that extensive literature searches citing safety of enzymes
211 from microbial sources support the general assumption that industrial enzyme
212 preparations from non-pathogenic organisms are safe (Olempska-Beer *et al.*, 2006).
213 Most engineered enzymes exhibit no greater amino acid sequence variability than

214 already exists for many isozymes in the diet (Préstamo & Manzano, 1993). Also, there
215 is no evidence to suggest that changes in amino acid sequence made through protein
216 engineering, to confer benefits such as tolerance to heat and/or pH or to simply
217 increase yield, will result in an otherwise safe enzyme being rendered toxic. That said,
218 comparing the amino acid sequence of an enzyme against the sequence of known
219 toxic proteins using *in silico* methods is one way to exclude the very remote possibility
220 that the enzyme may be toxic or have some physiological effect.

221

222 2. *Toxicological assessments of enzyme preparations*

223

224 Enzyme preparations contain either one major active enzyme that catalyzes a
225 specific reaction during food processing or two or more active enzymes that catalyze
226 different reactions. Each enzyme preparation must comply with the identity and
227 purity specifications, which are established for each enzyme preparation.

228 While food enzyme preparations are considered unlikely to cause any acute toxicity,
229 genotoxicity, or repeat-dose oral toxicity, it is the fermentation product(s) of
230 microorganisms from the manufacturing process that is/are of interest due to the
231 potential presence of secondary metabolites that may induce toxicity when ingested
232 (eg. aflatoxins, fumonisins and/or ochratoxins) (OECD, 2018). The fermentation
233 product, which also includes the food enzyme of interest, has traditionally been used
234 in genotoxicity tests and in repeat-dose rodent feeding studies submitted to JECFA.

235 The *General Specifications and Considerations for Enzyme Preparations Used in*
236 *Food Processing* that was published by JECFA (2006) and the Scientific Committee on
237 Food (SCF, 1992) elaborated the points of potential toxicological concern noting that:

238 a. Different strains belonging to the same species can behave differently. For
239 many microorganisms it is known that some of the strains in one species are
240 harmless, while others belonging to the same species may produce toxins.

241 b. For some fungal genera, especially *Penicillium* and *Aspergillus*, there have been
242 many misidentifications of fungal isolates. Consequently, there is a risk of
243 misclassification of fungal strains. For example, in some cases it has been

244 difficult to distinguish *A. oryzae* from *A. flavus*; the latter may produce
245 aflatoxins. As there is a risk of misidentification of microbial isolates, it is very
246 important that the microorganism used is correctly identified and, in case of
247 doubt, the identity should be verified by an independent, recognized
248 laboratory.

249 c. The ability of microorganisms to turn on genes that code for toxins can depend
250 on fermentation conditions such as the composition of fermentation media,
251 pH, temperature and fermentation period. Therefore, there is a risk that a
252 microorganism which does not produce toxins under some conditions
253 produce toxins under other conditions.

254 d. The continuous selection processes applied to source microorganisms in order
255 to maximize and optimize enzyme production may result in spontaneous
256 mutations which give rise to the possibility of changing a non-toxin-producing
257 strain into a toxin-producing strain, providing its genetic predisposition is
258 such that these mutations are sufficient to turn on the expression of toxin
259 producing genes.

260 e. There is a considerable potential to apply new techniques of genetic
261 modification in the production of food enzymes. Along with the introduction
262 of desirable traits, there is also the potential for introducing or deleting genes
263 for toxin production and, therefore, there is a need to explicitly characterize
264 and evaluate the genetic construct in the host, vector and insert.

265 As a result of these safety concerns, the toxicological testing requirements are:

266 a. For enzymes derived from edible parts of animals or plants no toxicological
267 tests are normally required. However, when enzymes are derived from parts
268 which are not generally considered as part of the normal diet, some toxicological
269 testing may be required unless other satisfactory documentation for safety in use
270 is provided.

271

272 b. For enzyme preparations derived from microorganisms, the toxicological tests
273 shall, where possible, be performed on batches of the final purified, concentrated
274 fermentation product before addition of formulation ingredients (e.g. carriers,
275 diluents, etc). The following tests are normally required:

276 i. 90-Day oral toxicity test in a rodent species;

277 ii. Two short-term tests:

278 1. A test for gene-mutations in bacteria,

279 2. A test for chromosomal aberrations (preferably *in vitro*).

280

281 3.1 *Dietary exposure and Margin of Exposure (MoE)*

282 Dietary exposure is calculated on the basis of the total organic solids (TOS)
283 content in the final (commercial) enzyme preparation and is usually expressed in
284 milligrams or micrograms TOS per kilogram body weight per day. TOS encompasses
285 the enzyme component and other organic material derived from the production
286 organism and the manufacturing process while excluding intentionally-added
287 formulation ingredients. JECFA then considers the estimated dietary exposure to an
288 enzyme preparation based on the proposed uses and use levels in food and relates it
289 to the NOAEL in its hazard assessment in order to determine an MoE.

290

291 3.2 *Exemptions from the basic toxicological requirements*

292

293 The original SCF and JECFA guidelines, which described exemptions from
294 performing toxicological bioassays in the safety assessments for enzymes, are:

295 a. From a toxicological point of view, it is important to perform a toxicological
296 testing procedure on each specific enzyme preparation produced from a
297 microbiological source. If, however, one enzyme from a specific strain has
298 been thoroughly tested and the manufacturing process does not differ

299 significantly for other enzymes from the same strain, the full testing battery
300 may be waived for such enzymes. This will be decided on a case-by-case basis.

301
302 b. If the microorganism used in the production has a long history of safety in food
303 use, belongs to a species that has been well-documented, does not produce
304 toxins, and the strain itself is of well documented origin, the acceptance of an
305 enzyme preparation from such a microorganism with no specific toxicological
306 testing may be justified. In this case, a correct and confirmed identification of
307 the microorganism is of paramount importance.

308
309
310 Thus far, there are very few examples of these exemptions from toxicological
311 testing being considered in a safety assessment of enzymes by JECFA. This may be
312 because of the uncertainty regarding compliance with the requirements of
313 accurately identifying the microbial strain and assessing the ability of the
314 microorganism to produce toxins. However, these requirements can more easily be
315 met with current technologies such as analytical molecular biology techniques, for
316 example, full genome sequencing, gene probing or RNA-Seq technologies, to
317 minimize misidentification (Yu *et al.*, 2011) and biochemometrics (Inui *et al.*, 2012)
318 to identify and quantify secondary metabolites in complex natural product mixtures
319 that may result from microbial fermentation..

320 **Classification of Enzymes**

321 To aid in the decision-making process for whether toxicological studies are required, JECFA
322 has grouped enzyme preparations for use in food into the following classes:

323 1. *Class I: Enzymes derived from sources which are considered safe for consumption and*
324 *for which toxicological evaluations are NOT normally required*

325 This class which also includes immobilized enzymes from these sources, can be
326 further categorized into:

327 i. Type i: Enzymes obtained from edible tissues of plants or animals commonly used
328 as foods.

329 These enzymes are regarded as foods and, consequently, their safety is
330 considered acceptable, provided that satisfactory chemical and microbiological
331 specifications can be established (e.g. papain, rennet).

332

333 ii. Type ii: Enzymes derived from microorganisms that are traditionally accepted as
334 constituents of foods or are normally used in the preparation of foods.

335 These products are regarded as foods and, consequently, their safety is
336 considered acceptable, provided that satisfactory chemical and microbiological
337 specifications can be established. (e.g. *Saccharomyces* sp.).

338

339 iii. Type iii: Enzymes derived from a Safe Food Enzyme Production Strain or a
340 Presumed Safe Progeny Strain (for definitions see *Annex 2*).

341 For enzyme preparations in this group, a detailed chemical and
342 microbiological narrative needs to be provided confirming that the source
343 organism producing a food enzyme has undergone appropriate toxicological
344 testing (i.e. repeat dose toxicity and genotoxicity testing) together with a thorough
345 chemical characterization of the enzyme concentrate and genomic analysis. This
346 could be demonstrated with published or unpublished genomic sequence data of
347 the genetically modified micro-organism to exclude the possibility of secondary
348 metabolite toxin genes. Safety assessments for these food enzymes should also
349 include appropriate information or other experimental data to determine their
350 potential to cause an allergic reaction when ingested.

351

352 On completion of appropriate toxicological testing of the fermentation product from
353 a production micro-organism, the guidelines anticipate that it should be possible to
354 conclude that the micro-organism can be classified as a source that is considered safe for
355 human consumption. Such a declaration was made for *A. oryzae* at the 68th meeting of
356 JECFA in 2008 (JECFA, 2008). Up until 2018, JECFA has evaluated over 80 food enzyme
357 preparations from a variety of micro-organisms and has never recorded a positive result
358 in any toxicity study, suggesting that either toxins were not present or were present at
359 levels that were below the limit of detection of the bioassays. These data suggest that

360 there are many strains of microorganisms which JECFA has previously reviewed (e.g.
361 *Bacillus subtilis*, *B. licheniformis*, *Aspergillus niger* and *A. oryzae*) that are considered to be
362 sources of food enzymes that are safe for human consumption. Therefore, provided the
363 genetic modification of the production organism, either as the result of the use of
364 recombinant-DNA or chemical mutagenesis, was well characterized, additional
365 toxicological testing would not be required. However, as already described in the 2006
366 JECFA guidelines, information on other aspects of enzyme production would be still
367 required (see Annex 3).

368

369 ii. Class II: *Enzymes derived from sources which are NOT considered safe for*
370 *consumption*

371 For all enzymes that do not fall under any of the sub-categories listed above and
372 which have not been previously reviewed by JECFA, chemical and microbiological
373 specifications must be established. Each enzyme must be evaluated and an ADI must be
374 established.

375 For enzymes derived from strains of micro-organisms not previously considered by
376 JECFA, information is required about the taxonomy, genetic background, other aspects
377 related to safety of the strain, and commercial use in foods (if any). Enzyme preparations
378 derived from such micro-organisms should contain neither antibiotic inactivating
379 proteins at concentrations that would interfere with antibiotic treatment nor
380 transformable DNA that could potentially contribute to the spread of antibiotic
381 resistance.

382 The absence of micro-organism-derived secondary metabolites of toxicological
383 importance in the enzyme concentrate also needs to be confirmed. This can be achieved
384 by submitting the results of two genotoxicity (mutagenicity and clastogenicity) assays on
385 these enzymes, as well as a subchronic oral toxicity study. As an alternative to
386 genotoxicity testing for secondary metabolites in fermentation products, a detailed
387 chemical characterization of the extracts (e.g. confirmation that they do not contain
388 toxicologically significant amounts of mycotoxins or other toxic secondary metabolite
389 that are known to be synthesized by strains of the production microorganism species or

390 of species related to the production microorganism), can be performed using analytical
391 tests like high-performance liquid chromatography and/or mass spectrometry. This
392 must also be supported with detailed knowledge of the genomic sequence of any
393 genetically modified microorganisms to exclude the possible presence of secondary
394 metabolite toxin genes. Additional characterization of the enzyme protein would also be
395 required, for instance including a bioinformatics analysis of the amino acid sequence to
396 confirm the absence any potential allergenic epitopes or significant amino acid sequence
397 homology to known toxins.

398 References

- 399 Anderson SE, Long C, Dotson GS (2017) Occupational allergy. *EMJ* 2: 65-71
- 400 Astwood JD, Leach JN, Fuchs RL (1996) Stability of food allergens to digestion in vitro. *Nat*
401 *Biotechnol* 14: 1269–1273.
- 402 Bannon GA (2004) What makes a food protein an allergen? *Curr Allergy Asthma Rep* 4: 43–
403 46.
- 404 Bøgh KL, Madsen CB (2015) Food allergens: Is there a correlation between stability to
405 digestion and allergenicity? *Crit Rev Food Sci Nutr* 56: 1545–1567.
- 406 Codex Alimentarius (2003) Alinorm 03/34: Joint FAO/WHO Food Standard Programme,
407 Codex Alimentarius Commission, Twenty-Fifth Session. Appendix III, Guideline for the
408 conduct of food safety assessment of foods derived from recombinant-DNA plants, and
409 Appendix IV, Annex on the assessment of possible allergenicity, pp. 47–60
- 410 Codex Alimentarius (2009) Foods derived from modern biotechnology.
411 ftp://ftp.fao.org/codex/Publications/Booklets/Biotech/Biotech_2009e.pdf. last accessed
412 25 June, 2019
- 413 EHC 240 (2009) Principles and methods for the risk assessment of chemicals in food;
414 Environmental Health Criteria 240, Food and Agricultural Organization of the United Nations
415 and the World Health Organization. [Inchem.org/documents/ehc/ehc/ehc240_index.htm](http://www.inchem.org/documents/ehc/ehc/ehc240_index.htm)
- 416 FAO (2006) General specifications and considerations for enzyme preparations used in
417 food processing. Rome: Food and Agriculture Organization of the United Nations.
418 (<http://www.fao.org/3/a-a0675e.pdf>, last accessed 24 June, 2019).
- 419 FAO/WHO (2001) Evaluation of allergenicity of genetically modified foods. Report of a Joint
420 FAO/WHO Expert Consultation on Allergenicity of Foods Derived from Biotechnology, 22–
421 25 January 2001. Rome, Italy, Food and Agriculture Organization of the United Nations
422 (<http://www.fao.org/3/a-y0820e.pdf>, last accessed 9 July 2019).
- 423 Fu TJ, Abbott UR, Hatzos C (2002) Digestibility of food allergens and nonallergenic proteins
424 in simulated gastric fluid and simulated intestinal fluid—a comparative study. *J. Agric Food*
425 *Chem* 50: 7154–7160.

426 Green BJ, Beezhold DH (2011) Industrial Fungal Enzymes: An Occupational Allergen
427 Perspective. *J. Allergy*, Article ID 682574.

428 Inui T, Wang Y, Pro SM, Franzblau SG, Pauli GF (2012) Unbiased evaluation of bioactive
429 secondary metabolites in complex matrices. *Fitoterapia*. 83: 1218-1225.

430 JECFA (2008) Asparaginase from *Aspergillus oryzae* expressed in *Aspergillus oryzae*. Sixty-
431 eighth Meeting
432 [https://apps.who.int/iris/bitstream/handle/10665/43870/9789241209472_eng.pdf?seq](https://apps.who.int/iris/bitstream/handle/10665/43870/9789241209472_eng.pdf?sequence=1)
433 [uence=1](https://apps.who.int/iris/bitstream/handle/10665/43870/9789241209472_eng.pdf?sequence=1), last accessed 25 June, 2019

434 JECFA (2016) Potential allergenicity of enzymes: change to the number of amino acids in
435 segments used in allergen database searches. Eightieth meeting. WHO technical report
436 series; no. 995. Accessed 9 July 2019.

437 Moreno FJ, Mellon FA, Wickham MSJ, Bottrill AR, Mills ENC (2005) Stability of the major
438 allergen Brazil nut 2A albumin (Ber e 1) to physiologically relevant in vitro gastrointestinal
439 digestion. *FEBS J*. 272: 341–352.

440 OECD Environment, Health and Safety Publications Series on Pesticides No. 98. (2018)
441 Working Document on the Risk Assessment of Secondary Metabolites of Microbial
442 Biocontrol Agents
443 [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2018)33&doclanguage=en)
444 [2018\)33&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2018)33&doclanguage=en); last accessed June 21, 2019

445 Olempska-Beer Z, Merker R, Ditto M, DiNovi M (2006) Food-processing enzymes from
446 recombinant microorganisms – a review. *Reg Tox Pharmacol* 45: 144-158.

447 Préstamo G, Manzano P. (1993) Peroxidases of selected fruits and vegetables and the
448 possible use of ascorbic acid as an antioxidant. *Hort Science* 28: 48-50.

449 Quirce S, Cuevas M, Díez-Gómez M, Fernández-Rivas M, Hinojosa M, González R, Losada E
450 (1992) Respiratory allergy to *Aspergillus*-derived enzymes in bakers' asthma. *J Allergy Clin*
451 *Immunol* 90: 970-978.

452 SCF (1992) Guidelines for the presentation of data on food enzymes. Opinion expressed on
453 11 April 1991. Reports of the Scientific Committee for Food, twenty seventh series.
454 http://aei.pitt.edu/40836/1/27th_good.pdf last accessed 25 June, 2019.

455 Schmidt DG, Meijer RJ, Slangen CJ, van Beresteijn EC (1995) Raising the pH of the pepsin-
456 catalysed hydrolysis of bovine whey proteins increases the antigenicity of the hydrolysates.
457 *Clin Exp Allergy* 25: 1007–1017.

458 Thomas K, Aalbers M, Bannon GA, Bartels M, Dearman RJ, Esdaile DJ, Fu TJ, Glatt CM, Hadfield
459 N, Hatzos C, Hefle SL, Heylings JR, Goodman RE, Henry B, Herouet C, Holsapple M, Ladics GS,
460 Landry TD, MacIntosh SC, Rice EA, Privalle LS, Steiner HY, Teshima R, Van Ree R, Woolhiser
461 M, Zawodny J (2004) A multi-laboratory evaluation of a common in vitro pepsin digestion
462 assay protocol used in assessing the safety of novel proteins. *Reg Tox Pharmacol* 39: 87–98.

463 US Pharmacopeia (2000) Simulated gastric fluid, TS. In: US Pharmacopeia Board of Trustees
464 (Ed.), *The National Formulary 9*. US Pharmacopeia Convention, Rockville, MD, pp. 2235.

- 465 Vanhanen M (2001) Exposure, sensitization and allergy to industrial enzymes. People and
466 Work Research Reports 46, Finnish Institute of Occupational Health, Department of
467 Pulmology, Helsinki University Central Hospital, Helsinki.
- 468 Vieths S, Reindl J, Müller U, Hoffmann A, Haustein D (1999) Digestibility of peanut and
469 hazelnut allergens investigated by a simple in vitro procedure. Eur Food Res Tech 209: 379–
470 388.
- 471 Wal JM (2001) Structure and function of milk allergens. Allergy 56: 35–38
- 472 Yagami T, Haishima Y, Nakamura A, Osuna H, Ikezawa Z (2000) Digestibility of allergens
473 extracted from natural rubber latex and vegetable foods. J Allergy Clin Immunol 106(4):
474 752–762.
- 475 Yu J, Fedorova ND, Montalbano BG, Bhatnagar D, Cleveland TE, Bennett JW, Nierman WC
476 (2011) Tight control of mycotoxin biosynthesis gene expression in *Aspergillus flavus* by
477 temperature as revealed by RNA-Seq. FEMS Microbiol Lett 322: 145-149.

478 **3. List of Recommendations for adoption by JECFA**

479

480 The Working Group recommends that JECFA considers:

481 1. The implementation [adoption] of:

482 a. The definition for Safe Food Enzyme Production Strain and Presumed Safe
483 Progeny Strain (*Annex 2*);

484 b. Revisions to Chapter 9.1.4.2 of EHC 240 pertaining to enzymes, including a
485 revision of the classification of enzymes and their definitions (Section 2);

486 c. A checklist of data requirements (*Annex 3*) for the risk assessment of enzyme
487 preparations in submissions for review by JECFA based on their assigned class
488 in the proposed revisions to Chapter 9.1.4.2 of EHC 240 (Section 2);

489 d. A list of terms and definitions as related to submissions of enzyme
490 preparations for use in food (*Annex 4*).

491 2. Whether an allergenicity assessment should be conducted on enzyme preparations
492 proposed for inclusion in all classes or only on proposals for Class I Type iii and Class
493 II as presented in Annex 2 and Questions 26 and 27 in Annex 3.

494 3. Whether the association between the establishment of an ADI and the presence of the
495 enzyme preparation in the final food can be considered unnecessary and reference to
496 the ADI can be deleted from the text in EHC 240 Chapter 9.1.2.4, as shown in Annex
497 2.

498 4. Whether it is appropriate to combine the consideration of immobilized enzyme
499 preparations that are in contact with foods only during processing with the
500 consideration of enzyme preparations added to foods but removed from the final
501 products (*Annex 2*).

502 5. Whether a separate online database should be established to present the combined
503 toxicological and specification information for enzyme preparations for use in food

504 evaluated by JECFA as a means of providing a simplified presentation of the data to
505 users (similar to the presentation currently used for flavourings).

506 6. Whether a separate JECFA identification number should be established to help
507 further identify enzyme preparations with completed JECFA safety evaluations
508 (similar to the JECFA numbering system used for flavourings).

509 7. Whether an enzyme-preparation-specific template for the submission of analytical
510 methods including method performance characteristics (method validation data) and
511 quality control data should be developed.

512

513

514

515 **4. List of Abbreviations**

516

517 ADI – Acceptable daily intake

518 ATCC – American Type Culture Collection

519 bw – body weight

520 CAS – Chemical Abstracts Service

521 CCFA - Codex Committee on Food Additives

522 EC – Enzyme Commission of the IUBMB

523 EHC 240 – Environmental Health Criteria 240 Principles and methods for the risk
524 assessment of chemicals in food

525 GMM – Genetically Modified Microorganisms

526 GMP – Good Manufacturing Practice

527 IUBMB – International Union of Biochemistry and Molecular Biology

528 JECFA – Joint FAO/WHO Expert Committee on Food Additives

529 NOAEL – No Observed Adverse Effect Level

530 NOEL – No Observed Effect Level

531 OECD – Organisation for Economic Co-operation & Development

532 SGF – Simulated Gastric Fluid

533 SCF – Scientific Committee on Food (Advisory body to the European Commission)

534 TOS – Total Organic Solids

535 *Annex 1. Draft Report on Enzyme Assessment for JECFA Food Additives*

536

537

538 **FAO JECFA Project to Review and Revise the Protocol for Enzyme Review**

539 **Richard Cantrill, PhD**

540 **FAO Consultant**

541

542

543 **Table of Contents**

544 1. Summary

545 2. Background

546 3. Data used

547 4. Introduction

548 4.1 Enzymes from microorganisms

549 4.2 Enzyme safety evaluation

550 4.3 Total Organic Solids (TOS)

551 4.4 Protein composition and allergenicity

552 4.5 Use levels and dietary exposure

553 4.6 Toxicological considerations

554 5. Review of the safety evaluation of food enzymes

555 5.1 Similar catalytic activities/specificity

556 5.2 Safe Strain Lineage

557 5.3 Protein sequence data

558 5.4 DNA sequence data

559 6. Possible requirements for the future review the safety of food enzymes

560 7. References

561 **1. Summary**

562

563 A number of documents are available regarding the evaluation of enzyme
564 preparations for safe use in the manufacture of food products. These documents have
565 been focused on the submission of relevant information to bodies such as JECFA, EFSA
566 and specific governments for approval for food use. The enzyme industry also has
567 produced documents related to the requirements for submissions for safety
568 evaluations. Most of the processes and procedures have been routed through the
569 Technology committee of the Enzyme Technical Association (ETA). ETA also hosts the
570 International Enzyme Coordination Group (IECG), whose members represent
571 regionally located professional enzyme associations and advocacy groups (ABIAM,
572 AMFEP, CERF, ETA and JEA). meetings were held in July and October 2018 with
573 members of the ETA Executive Committee to understand processes for enzyme
574 evaluation from an industry perspective and to discuss requirements for future
575 enzyme safety evaluations. A literature search generated surprisingly only a few
576 papers on the evaluation of food enzymes and included notifications of enzymes
577 evaluated by various bodies. From this research a proposal is made to streamline the
578 safety evaluation of enzymes used in food using experience gained in the JECFA safety
579 evaluation of flavors and JECFA discussions on information required for Modified
580 Starches.

581

582

583 **2. Background (taken from JECFA reports [WHO 2016])**

584

585 “In 1987, the Committee outlined criteria for evaluating the safety of enzymes
586 and proposed to categorize enzyme preparations into five main groups on the
587 basis of their origin: (i) animal tissues, (ii) portions of edible plants, (iii)
588 microorganisms traditionally accepted as constituents of food,
589 microorganisms normally used in the preparation of foods, (iv) non-
590 pathogenic microorganisms commonly found as contaminants of foods or (v)
591 microorganisms that are less well known. At the same time, the Committee
592 envisaged three cases for assessing the safety of enzymes in groups (iv) and
593 (v) – those added directly to food and not removed, those added to food but
594 removed, and immobilized enzyme preparations – and indicated guidelines
595 appropriate for evaluations of safety in each case (IPCS, 1987).”

596

597 “Enzymes produced by genetically modified microorganisms were not
598 considered at this time. Subsequently, the Committee evaluated several
599 enzymes in this category, including laccase from *Myceliophthora thermophila*
600 expressed in *Aspergillus oryzae* and xylanase from *Thermomyces lanuginosus*
601 expressed in *Fusarium venenatum*. The Committee evaluated the safety of
602 these enzyme preparations on the basis of toxicological data files, both of
603 which included a 90-day toxicity study in rats, and two *in vitro* genotoxicity
604 tests - a test for reverse mutations in bacteria and a test for chromosomal
605 aberrations in mammalian cells. The Committee allocated an ADI “not
606 specified” to these enzyme preparations.”

607
608 “The sixty-fifth Committee (FAO/WHO, 2006) evaluated an enzyme
609 preparation of phospholipase A1 produced by the same host strain of *A. oryzae*
610 that had been modified to produce other enzymes. It could not, however,
611 assess the safety of this preparation by comparison with the information
612 available on one of the other enzymes but acknowledged that alternatives to
613 toxicity testing such as evidence that no unintended compounds were present
614 in the enzyme preparation or a complete molecular characterization of the
615 enzyme production strain were acceptable. The Committee concluded that
616 guidelines should be drawn up for the safety assessment of enzymes produced
617 by genetically modified microorganisms. These guidelines should include the
618 essential information for various situations and details of molecular
619 characterization of the producing microbial strain necessary to allow
620 adequate assessment of the safety of the preparation.”

621
622 “At the sixty-eighth meeting of JECFA (FAO/WHO, 2007), the Committee
623 reviewed comments on these considerations submitted by the Enzyme
624 Technical Association and the Association of Manufacturers and Formulators
625 of Enzyme Products. The Committee also noted the ongoing international
626 initiatives to elaborate guidelines for the safety evaluation of enzymes
627 (including those from genetically modified microorganisms) and
628 microorganisms intended for food applications. These documents were
629 expected to be finalized shortly thereafter. The Committee recommended that
630 the subject of guidelines for the safety evaluation of enzymes produced by
631 genetically modified microorganisms be addressed at a future meeting.”

632
633 “At the seventy-first meeting of JECFA (FAO/WHO, 2010), the Committee
634 discussed the new regulation for enzymes enacted by the European
635 Parliament and related guidance documents. The Committee decided to
636 update the General Specifications and Considerations for Enzymes Used in
637 Food Processing (FAO, 2006) to expand recommendations for microbiology
638 and molecular biology information to be submitted in dossiers for enzymes
639 from microorganisms (including those from genetically modified
640 microorganisms) and to discuss toxicological and other safety studies for
641 enzymes from all sources. The Committee recommended the establishment of
642 a working group to update the current guidance document on enzymes for
643 discussion at a future meeting.”

644
645

646 **3. Data sources used in the preparation of this report**

647
648 Information was requested be email from a variety of national governments, trade
649 organizations and experts in the field who had previously indicated interest in the
650 topic. A number of positive responses were received from governments and technical
651 experts referencing published literature, documents and websites. the Enzyme Trade
652 Association represented the international consortium IECG including ABIAM, AMFEP,

653 CERF, ETA and JEA. Their support was augmented with two face-to face meetings and
654 phone calls. In addition, a literature search and Google searches were performed.
655

656 Source materials not directly referenced elsewhere include:

- 657 i. Documents and processes referred to by Australia, Canada, China,
658 Japan, USA
- 659 ii. IECG – representing ABIAM, AMFEP, CERF, ETA and JEA
- 660 iii. ETA - references from ETA website
- 661 iv. Literature search - (Enzymes AND food safety AND regulations) OR
662 (Enzymes AND food safety AND evaluation), 1997-2018 – conducted Jan
663 2018;
- 664 v. JECFA specifications – see enzyme evaluations in recent WHO/FAO
665 series
- 666 vi. EHC 240 (2009) Chapter 9.1.4.2
- 667 vii. GRAS Notifications
- 668 viii. EFSA reviews
669

670 671 **4. Introduction**

672
673 Enzymes are classified in the International Union of Biochemistry and Molecular
674 Biology (IUBMB) system into six major classes (IUBMB, 1992) (EC 1-6):
675 oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Each class
676 is subdivided into subclasses that are further subdivided. Each enzyme has an IUBMB
677 record consisting of the Enzyme Commission (EC) number and nomenclature and a
678 Chemical Abstract Service (CAS) number. In general, an enzyme name includes both
679 the substrate(s) and the reaction type, though in many situations the enzyme is
680 referred to by a shortened or trivial name, whereas the full name may be found in
681 JECFA, EFSA and other listings of approved enzymes for food use.
682

683 Enzymes are found in all living organisms and provide a variety of catalytic functions
684 necessary for cell viability. From a structural perspective, enzymes are composed of
685 single or multiple proteins made up of amino acids that are common to all proteins
686 found in food. Enzymes with the same catalytic activity have similar active site
687 configurations on a structural backbone of amino acids. When ingested, enzymes
688 from all sources, like most other proteins, are readily digested, absorbed and further
689 metabolized. While it has been noted that many food allergens are proteins, it is clear
690 that not all food proteins are allergens. Reviewing the amino acid sequence of an
691 enzyme against known allergenic sequences has become a key requirement in
692 determining the safety of enzymes.
693

694 The history of enzyme use in food applications is long and well known. Enzymes have
695 been sourced from animal tissues, plants and microorganisms. In some cases, the
696 microorganism is added to food during its preparation, e.g. bread-, cheese-, wine-,
697 beer-making, allowing the enzymes present to work on the food as part of processing
698 or maturation. More recently microorganisms have become a major source of

699 enzymes used as stand-alone technical treatments in the manufacture of food
700 ingredients and products.

701
702 A large number of enzymes used by the food industry are sourced from both native
703 and genetically engineered microorganisms (also termed genetically modified
704 microorganisms [GMM]). Enzyme are produced by controlled fermentation, followed
705 by removal of the production strain, purification and concentration and formulated
706 using food-grade raw materials.

707
708

709 **4.1 Enzymes from microorganisms**

710

711 Enzymes with specific catalytic activities have been identified in a large number of
712 microorganisms, but industrial scale enzyme production is limited to a small subset
713 of well-characterized microorganisms. The selection of such microorganisms relies
714 on the knowledge of their safety and ability to reliably produce enzymes under large-
715 scale, controlled, fermentation conditions. As knowledge of the safety of, and
716 experience with microorganisms has developed, a relatively small number of host
717 strains have been subjected to further genetic modification. Genetic modifications
718 may include:

- 719
- 720 ▪ improvements to strain stability and performance in large scale
- 721 ▪ incorporation of genetic material coding for enzymes from the same or
- 722 from other well-characterized donor microorganisms
- 723 ▪ deletion of genes capable of producing toxins or other undesirable
- 724 metabolites
- 725 ▪ improvement of the functionality of the desired enzyme (e.g. enhanced
- 726 stability and performance in different environments such as pH,
- 727 temperature)
- 728


729 In the development and characterization of native and recombinant strains, the
730 inserted DNA and in some cases the complete genome of the organism has been
731 sequenced. The large body of knowledge about specific host organisms and the safety
732 of the inserted DNA contribute to the overall safety of the enzymes produced.

733
734 From a production perspective, the enzyme should be produced in large quantities by
735 a well-characterized microorganism under fermentation conditions that do not stress
736 the organism or lead to the production of toxic materials. In a system similar to Good
737 Manufacturing Practice, enzymes from microorganism are produced according to
738 Good Large Scale Fermentation Practices in line with guidelines published by OECD
739 (OECD, 1992).

740
741 Since a limited number of well characterized microorganisms has been exploited by
742 the food enzyme industry, their history of use and growth characteristics in culture
743 have been well documented. The regular use has led to the development of the Safe
744 Strain Lineage concept (SSL) by the food enzyme industry. Originally proposed by

745 Pariza & Foster (1983), SSL has been revisited and strengthened on a number of
 746 occasions since then (see figure 1). Supported by IECG and their international
 747 industry members, the decision tree approach allows food enzyme manufacturers to
 748 assess likely safety concerns and make appropriate decisions on the use of the host
 749 strain and its gene-modified counterparts. The decision tree approach addresses
 750 concerns regarding the production strain, the host strain, the inserted DNA as well as
 751 the safety of the enzyme and possible antibiotic resistance, presence of antibiotics
 752 and toxic metabolites.

753
 754 EFSA has also developed Qualified Presumption of Safety (QPS) for microorganisms
 755 used in production of food enzymes and the US FDA has released enzyme guidance
 756 and a final rule on GRAS evaluations (REFS).
 757



758
 759 Fig.1. Decision tree proposed by Pariza & Johnson (2001) as provided; courtesy of
 760 ETA, July 2018.

761
 762
 763 **4.2 Current enzyme safety evaluation**

764
 765 Enzyme preparations for food use have been grouped for safety evaluation according
 766 to the following criteria:

- 767 a) enzyme preparations added directly to food but not removed; e.g. enzymes
- 768 used in bakery applications;

- 769 b) enzyme preparations added to food but removed from the final product
 770 according to Good Manufacturing Practice (GMP); e.g. enzyme preparations
 771 used the preparation of food ingredients from complex starting materials such
 772 as carbohydrases; or
 773 c) immobilized enzyme preparations that are in contact with food only during
 774 processing; e.g. immobilized lipase and phospholipases.
 775

776 These three categories reflect varying degrees of likelihood of the enzyme or other
 777 components of the enzyme preparation being present in the finished food. In terms
 778 of likelihood, case b) reflects only traces of enzyme and organism/medium
 779 components that might be left behind, and case c) covers the possibility of cross-
 780 linking reagents or support components (monomers) being leached during
 781 processing. The primary safety concern in each case is not the enzyme itself but the
 782 presence of potential toxins in the preparations. For immobilized enzymes it was
 783 potential genotoxins leaching from some cross-linking agents (e.g. ethylenimine from
 784 polyethylenimine) used to immobilize the enzyme. For the other two it was mainly to
 785 confirm a safe level of secondary metabolites formed through microbial fermentation
 786

787 In general, the safety evaluation of enzymes is covered under the headings shown in
 788 Table 1 taken from the JECFA (JECFA, 2006) requirements.
 789

Table 1. Considerations for enzyme preparations	
i.	Classification and Nomenclature
ii.	Enzyme preparations
iii.	Active components
iv.	Source materials (source and production strain details)
v.	Formulation (total organic solids, TOS)
vi.	Other considerations
	a. Microorganism safety
	b. rDNA modifications and products
vii.	Allergenicity
viii.	Exposure
ix.	Toxicology
x.	Additional information for consideration

790
 791
 792

793 4.3 Enzyme preparations and Total Organic Solids (TOS)

794
 795 The product of fermentation that is of interest for the safety assessment is the article
 796 of commerce which may contain other excipients, stabilizers, etc. in addition to the
 797 enzyme in question. If the secondary components have been previously assessed and
 798 are of food grade quality, then focus is on the enzyme itself and any carryover from
 799 the culture medium and the microorganism. This material is termed Total Organic
 800 Solids (TOS) and is the sum of the enzyme protein together with other carryover

801 materials. The same material is routinely used in in vitro and in vivo toxicological
802 testing, however, its relationship to the final article(s) of commerce is required for
803 the safety evaluation.

804
805

806 **4.4 Proteins and allergenic potential**

807

808 Proteins are an important part of the daily diet and are present in common foods. In
809 foods consumed raw, enzymes are ingested in an active conformation whereas most
810 are inactivated by food processing or cooking. Proteins are usually digested in the
811 gastrointestinal tract to form peptides and amino acids. Therefore, enzymes added to
812 food are unlikely to be absorbed in their native forms in significant amounts.
813 However, most food allergens survive degradation in order to initiate or elicit an
814 immunological response.

815

816 In 2001, the FAO and WHO convened a workshop to discuss the ‘Current Approach to
817 Determine the Allergenicity of Genetically Modified Foods (Decision Tree Approach)’.
818 The workshop report states that “food allergies are adverse reactions to an otherwise
819 harmless food or food component that involves an abnormal response of the body’s
820 immune system to specific protein(s) in foods. True food allergies may involve several
821 types of immunological responses. However, the most common types of food allergies
822 are mediated by allergen-specific immunoglobulin E (IgE) antibodies.

823

824 Almost all food allergens are proteins, although the possibility exists that other food
825 components may act as haptens. While the crops from which staple foods are derived
826 contain tens of thousands of different proteins, relatively few are allergenic. However,
827 altered dietary preferences can have significant implications for the development of
828 food allergies. For example, allergy to peanut (groundnut) occurs at a significant
829 frequency in North America and Western Europe but not in other countries where
830 peanuts are less commonly eaten. Also, recent food introductions such as kiwi fruit
831 have proven to be additional sources of food allergens. These observations provide
832 confidence that there are not a large number of potential allergens in the food supply,
833 but show that new allergenic foods are sometimes introduced into the marketplace.
834 Because of the above, a clear need exists to pay particular attention to allergenicity
835 when assessing the safety of foods produced through genetic modification.

836

837 The Codex Alimentarius Commission has adopted a list of the most common
838 allergenic foods associated with IgE-mediated reactions on a world-wide basis that
839 includes peanuts, soybeans, milk, eggs, fish, crustacea, wheat, and tree nuts. These
840 commonly allergenic foods account for over 90% of all moderate to severe allergic
841 reactions to foods, although an extensive literature search has revealed more than 160
842 foods associated with sporadic allergic reactions’ (FAO/WHO 2001).

843

844 Since some enzymes used in food applications are extracted from natural sources or
845 produced by native microorganisms by fermentation, their historic and regular use
846 has been considered sufficient to exempt them from consideration as allergens. There

847 have been no reports of allergenic reactions from finished foods using GMM enzymes
848 in their production. Only adverse reactions following direct inhalation or skin or eye
849 contact with high levels of work-place exposure to food enzymes have been reported
850 (Ladics & Sewalt, 2018).

851
852 The amino acid sequence of an enzyme can be probed in silico, using algorithms
853 such as FAST-All (FASTA) and Basic Local Alignment Search Tool (BLAST), against
854 various databases (e.g. AllergenOnline, and National Center for Biotechnology
855 Information (NCBI) that contain sequences of known allergens (Ladics et al., 2011).
856 Both bioinformatic methods (FASTA and BLAST) rely on assessing the probability
857 that an alignment between a query sequence (the unknown protein) and a sequence
858 in the database occurs by chance. Full length alignment, 80 amino acid alignments
859 and 8 amino acid exact matches may be performed. However, Allergen Online states:

860
861 “In our experience, isolated identity matches of 8 contiguous amino acids occur by
862 chance alone at some modest rate, matches of 7 and 6 occur more
863 commonly. Experience (published and unpublished) demonstrates that two proteins
864 sharing only a single short identity match of from 6 to 8 contiguous amino acids do
865 not share IgE binding in the absence of more extensive identity alignments (at least
866 >35% identity over 80 or more amino acids). And that sequences sharing less than
867 50% identity over their full-lengths are rarely cross-reactive. Thus we recommend
868 not using these short identity matches as there is no scientific evidence that they
869 predict IgE cross-reactivity and they do not predict shared clinical activities.”

870
871 A negative sequence homology result indicates that a newly expressed protein is not
872 a known allergen and is unlikely to be cross-reactive to known allergens. A result
873 indicating absence of significant sequence homology should be considered along with
874 other data (e.g. resistance to protease digestion) in assessing the allergenic potential
875 of microbial expressed enzymes. In deciding about allergenic potential, there is
876 always the possibility of the creation of a *de novo* allergen through enzyme protein
877 digestion.

878
879
880 **4.5 Use levels and dietary exposure**

881
882 Use levels of enzymes in food production are very low (g enzyme/kg ingredients).
883 Enzymes are added to carry out a specific function in the production of a variety of
884 food products. In some cases, they are added at early stages of production to
885 breakdown starch or other macromolecular precursors of a food ingredient such as
886 corn syrup or distilled alcohol. In these cases, the enzyme is removed from the final
887 product during different manufacturing steps. In other cases, such as bakery
888 applications, the enzyme is expected to be heat inactivated with the possibility of still
889 being intact and a potential allergen in the final product. Calculating the level of
890 enzyme use in a food is dependent on the process used, the recipe/formulation and
891 the number of different ingredients present in the enzyme preparation. In the
892 calculation of dietary exposure, it is also assumed that all of the enzyme used will
893 appear in the final food, and all of a specific food type contains the enzyme at the

894 maximum use level. This provides the basis for an estimate of dietary exposure to be
895 very conservative.

896
897 Though a number of different approaches have been considered over the years, the
898 Budget Method has been most often used and accepted. Recently, as an attempt to
899 add more reliability to the exposure calculation, EFSA has launched a new database
900 to collect data from Member States (EFSA, 2018):

901
902 “The Food Enzyme Intake Model (FEIM) is a tool for estimating chronic dietary
903 exposure to food enzymes used in food processes. FEIM follows the
904 methodology recommended in the CEF Panel’s Statement on Exposure
905 assessment of food enzymes. It has been developed on the basis of summary
906 statistics of food consumption data collected from Member States (stored in
907 the EFSA Comprehensive European Food Consumption Database).

908 FEIM comprises process-specific calculators, such as FEIM-baking or FEIM-
909 brewing, which allow estimation of dietary exposure to food enzymes used in
910 individual food manufacturing processes. Exposure results are reported at
911 mean and high level for different population groups (e.g. infants, toddlers,
912 adults, etc.) in different countries.”

913 These individual food application databases are in early stages of development and
914 may only be of use once completed by the relevant organizations in the EU member
915 states. Other national bodies may use the Budget Method, consumption data and use
916 levels when determining an estimate of dietary intake. The US FDA uses a similar
917 approach to EFSA in calculating the dietary exposure to enzyme preparations added
918 to food by considering publicly available food consumption databases. US FDA also
919 uses market disappearance and annual poundage data to approximate per capita
920 exposure estimates.

921
922

923 **4.6 Current toxicological considerations**

924
925 A small number of tests have been routinely applied to enzymes of microbiological
926 origins. OECD recommends results from two in vitro assays (bacterial reverse
927 mutation assay, in vitro chromosomal aberration assay, micronucleus test or mouse
928 lymphoma tk assay) and a 90-day sub-chronic oral toxicity study are performed
929 (OECD 408, 471 and 487). It has been proposed that some or all of this testing may be
930 avoided if the enzyme and its production strain are well-characterized and sufficient
931 test results are available for the host strain or for a closely related production strain.
932 Since it is likely that the enzyme itself is not the cause of any irregular test results,
933 these tests primarily provide information about the balance of the organic material
934 in the TOS. Since many of the newly developed microorganism have been modified in
935 such a way as to delete genes responsible for the production of toxins and are
936 cultivated under conditions that do not cause stress and the production of toxins, it
937 has been proposed that this type of testing may not be required and could be replaced

938 by direct analysis for toxins and a weight-of-evidence approach (Ladics & Sewalt,
939 2018) considering data generated in related production strains.

940
941 Data from numerous enzymes preparations have been submitted for review by EFSA,
942 JECFA and US FDA GRAS, wherein safety has been assured by data from in vitro and
943 in vivo studies that in most cases show negative findings at the highest doses tested.
944 Hence a Margin of Exposure (calculated as: mg TOS/kg bw per day (calculated dietary
945 exposure) vs NOAEL or NOEL obtained from a 90-day oral toxicity study) can be large.

946
947

948 **5. Review of the safety evaluation of food enzymes**

949

950 In 2006, JECFA published its most recent guidance on the evaluation of enzymes for
951 use in food. A literature search indicated very few advances in the consideration of
952 food enzyme safety since that time. The main focus has been on the assurance of
953 safety of microorganisms used in enzyme production. However, the publications of
954 Pariza, et al. EFSA, US EPA and ETA have contributed newer considerations of the
955 approach to dealing with enzyme safety.

956

957 The present JECFA Priority list for safety evaluation contains 29 enzyme
958 preparations. To reduce this backlog, it is thought necessary to evaluate the current
959 process and determine if a more streamlined process can be implemented.
960 Considering the current state of the art of enzyme production by microorganisms,
961 there are a number of ways in which the process could be improved.

962

963 Certain factors indicate possible ways to consider enzyme safety that may lead to
964 greater progress in enzyme safety evaluations (Table 2). A number of these factors
965 are described below:

966

967 Table 2. Possible factors affecting Enzyme Assessment

968

Drivers for simplification	Constraints
Safe strain lineage concept	DNA stability/instability, toxigenicity and pathogenicity
Enzymes with the same specificity	Strain performance/productivity Similarities in primary sequence
Enzymes from the same source organism	Scale up Enzyme activity and TOS
GMP production	Toxin production Specifications Enzyme purity in TOS
Absence of production strain in final product	Secondary metabolites and residual medium components

Read-across for safety evaluation	Requirement for whole genome sequencing and modification identification Allergenicity Prediction of toxicity Digestibility Heat stability
Dietary exposure level	A consistent method of assay using generally-available substrates Use and use level dependent

969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002

5.1 Similar catalytic activities/specificity

A number of enzymes have been developed by various industry players to meet the needs of food ingredient processors and formulators. Such innovations include the development of enzymes with the same catalytic specificity but with different tolerances to conditions such as heat or pH and yield.

For Discussion: Is it possible to assume that all enzymes with the same catalytic specificity would be equally safe from a food safety evaluation perspective? If so, what additional data would be required to satisfy the food safety assessor?

5.2 Safe Strain Lineage

The development of lists of microorganisms that have a history of safe use as production strains is a step in the right direction in the assurance of safety of use. A number of cases have been presented to both EFSA and the US FDA (GRAS submission) that use a “Read-Across” approach in providing safety data for stable host strains and also for other individual production strains modified to produce different enzymes to support the safety of a newly derived production strain and its enzyme product.

For Discussion: If a history of testing can be established and assurance that the strain in question does not produce toxins as a result of the most recent modification, can this information provide sufficient assurance that the enzyme preparation is safe under normally accepted conditions of use?

5.3 Protein sequence data

Knowledge of the amino acid sequence of the enzyme is required for the *in silico* determination of potential allergenicity.

1003 **For Discussion:** Taken together with a determination of process stability (heat,
1004 pressure, etc.), digestibility and catalytic activity, can sufficient data be accumulated
1005 to assure the safety of the enzyme when used in appropriate levels?
1006

1007
1008 **5.4 DNA sequence data**
1009

1010 As part of the knowledgebase on a particular production strain, a full DNA sequence
1011 of the organism is preferred. However, a DNA sequence of the inserted gene(s) is
1012 required and can be used to confirm the primary structure of the enzyme protein.
1013 Where synthetic DNA has been used to create the gene, the chances of unintended
1014 consequences is reduce compared with the use of DNA extracted from another
1015 microorganism.
1016

1017 **For Discussion:** Is there a difference in risk if the inserted gene(s) are synthesized *de*
1018 *novo* or extracted from other microorganisms? Gene insertion is only of relevance if
1019 it is possible for the inserted gene to affect the production of toxic metabolites.
1020

1021
1022 **6. Possible requirements for the future review the safety of food enzymes**
1023

1024 In evaluating the list of options for the simplification of the enzyme review process it
1025 is apparent that there are a number of items that parallel the safety assessment of
1026 flavors (see Table 3). These include:
1027

Table 3.	
Flavors	Enzymes
Structural similarities	Similar catalytic activities
Extremely low use levels	Low use levels defined by function
Read-across approach for toxicology	Safe Strain Lineage and industry knowledge
Multiple isomers	Secondary activities
Residual synthetic byproducts and/or contaminants	TOS Toxic metabolites

1028
1029 It was also noted that there are similarities between food enzyme evaluation and the
1030 definition of Modified Starches where products are manufactured to meet a
1031 functional requirement; structures are related and of little toxicological concern; data
1032 gaps may be filled by “Read-Across” from related materials.
1033

1034 Therefore, it is proposed that many of these similarities are applied to the safety
1035 assessment of food enzymes in order to demonstrate their safety. Information
1036 required for assessment would be modified, but the approach would be “fill in the
1037 boxes” and consider toxicological evidence.

Table 4. Details of the information required for enzyme safety assessment	
information required	Detail
i. Classification and Nomenclature	According to IUBMB including full name and synonyms
ii. Enzyme preparation(s) (total organic solids, TOS)	Description of enzyme material and any carryover from the fermentation as used in toxicological testing
iii. Active components	Enzyme activity or activities present, definition of catalytic activity
iv. Source materials (source and production strain details)	Definition of the production strain organism and the origins of the expressed enzyme
v. Formulation	Other components added to the enzyme preparation for commercial use, such as excipients and stabilizers
vi. Other considerations	
a. Microorganism safety	History of derivation of the microorganism and development of host strain(s), including names and any name changes during the development of the host strain and production strain
b. rDNA modifications and products	Details of DNA modifications made and techniques used, sources of DNA added and identification of DNA removed
vii. Allergenicity	Results of comparison of primary amino acid structure with allergen databases
viii. Exposure	Levels of use in food ingredient and final food production
ix. Toxicology	Results of recommended toxicological testing for the enzyme including results from other members of the same family production strains and the host strain
x. Additional information for consideration	
xi. Test method and units	A universally usable test method to define enzyme activity present in the preparation

1040 **7. References**

- 1041
- 1042 AllergenOnline <http://www.allergenonline.com>
- 1043
- 1044 Australia: Australia and New Zealand Food Standards Code, Schedule 3.
- 1045 <http://www.foodstandards.gov.au/code/Pages/default.aspx> last accessed 24 August. 2018
- 1046
- 1047 Australia: Food standards Australia New Zealand, Application Handbook, Guideline 3.3.2
- 1048 <http://www.foodstandards.gov.au/code/changes/pages/applicationshandbook.aspx> last
- 1049 accessed 24 August, 2018
- 1050
- 1051 Canada: Food Additives – Submission Preparation [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/food-additives-submission-preparation.html)
- 1052 [canada/services/food-nutrition/food-safety/food-additives/food-additives-submission-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/food-additives-submission-preparation.html)
- 1053 [preparation.html](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/food-additives-submission-preparation.html)
- 1054
- 1055 Canada: A Guide for the Preparation of Submissions on Food Additives
- 1056 [https://www.canada.ca/en/health-canada/services/food-nutrition/reports-](https://www.canada.ca/en/health-canada/services/food-nutrition/reports-publications/guide-preparation-submissions-food-additives.html)
- 1057 [publications/guide-preparation-submissions-food-additives.html](https://www.canada.ca/en/health-canada/services/food-nutrition/reports-publications/guide-preparation-submissions-food-additives.html)
- 1058
- 1059 Canada: Enzymes used in food processing [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/enzymes-used-processing.html)
- 1060 [canada/services/food-nutrition/food-safety/food-additives/enzymes-used-](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/enzymes-used-processing.html)
- 1061 [processing.html](https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/enzymes-used-processing.html)
- 1062
- 1063 China: Background to ILSI meeting June 2018 – see Exhibit 1.
- 1064
- 1065 EFSA – QPS Introduction of a Qualified Presumption of Safety (QPS) approach for
- 1066 assessment of selected microorganisms referred to EFSA – Opinion of the Scientific
- 1067 Committee. The EFSA Journal 2007, 293, 1–85.
- 1068
- 1069 EFSA – Guidance on EFSA prepared by the Scientific Panel of Food Contact Materials,
- 1070 Enzymes, Flavourings and Processing Aids on the Submission of a Dossier on Food
- 1071 Enzymes. The EFSA Journal (2009) 1305, 1-26 (revised 2013)
- 1072 <https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2009.1305>
- 1073
- 1074 EFSA - Food Enzyme Intake Model
- 1075 <https://www.efsa.europa.eu/en/applications/foodingredients/tools> (last accessed 17
- 1076 October, 2018)
- 1077
- 1078 EHC 240 - Principles and Methods for the Risk Assessment of Chemicals in Food; principles
- 1079 related to specific groups of substances Chapter 9.
- 1080 http://www.inchem.org/documents/ehc/ehc/ehc240_chapter9.pdf last accessed 20
- 1081 October, 2018
- 1082
- 1083 Enzyme Technical Association - References supplied by ETA and available from ETA
- 1084 website <http://www.enzymeassociation.org>
- 1085

1086 FAO/WHO (2001) Expert Consultation on Foods Derived from Biotechnology
1087 <http://www.fao.org/ag/agn/food/pdf/bi03al.pdf>, last accessed 30 October, 2018
1088
1089 FAO/WHO (2006). Evaluation of certain food additives. Sixty-fifth report of the Joint
1090 FAO/WHO Expert Committee on Food Additives. Geneva: World Health Organization (WHO
1091 Technical Report Series, No. 934; http://whqlibdoc.who.int/trs/WHO_TRS_934_eng.pdf,
1092 last accessed 20 September, 2018).

1093 FAO/WHO (2007). Evaluation of certain food additives and contaminants. Sixty-eighth
1094 report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva: World Health
1095 Organization (WHO Technical Report Series, No. 947;
1096 http://whqlibdoc.who.int/publications/2007/9789241209472_eng.pdf, last accessed 20
1097 September, 2018).

1098 FAO/WHO (2010). Evaluation of certain food additives. Seventy-first report of the Joint
1099 FAO/WHO Expert Committee on Food Additives. Geneva: World Health Organization (WHO
1100 Technical Report Series, No. 956; http://whqlibdoc.who.int/trs/WHO_TRS_956_eng.pdf,
1101 last accessed 20 September, 2018).

1102 FAO (2006). General specifications and considerations for enzyme preparations used in
1103 food processing. Rome: Food and Agriculture Organization of the United Nations
1104 (<http://www.fao.org/docrep/009/a0691e/A0691E03.htm>; last accessed November, 2018)

1105 IECG charter supplied by ETA – see Exhibit 2.
1106

1107 IPCS (1987). Principles for the safety assessment of food additives and contaminants in
1108 food. Geneva: World Health Organization, International Programme on Chemical Safety
1109 (Environmental Health Criteria 70;
1110 <http://www.inchem.org/documents/ehc/ehc/ehc70.htm>, last accessed 17 October, 2018).

1111 IUBMB - Biochemical Nomenclature Committees; Enzyme Nomenclature
1112 <http://www.sbcs.qmul.ac.uk/iubmb/enzyme/> (last accessed 20 October, 2018)
1113

1114 Japan: Provisional translation of Guidelines for the Risk Assessment of Additives (Enzymes)
1115 in Foods (in Japan)
1116 http://www.fsc.go.jp/hyouka/index.data/For_HP_Guidelines_for_Enzymes.pdf#search=%277Guidelines+for+the+risk+assesment+of+additives+%28Enzymes%29in+Foods%27; last
1117 accessed December, 2018)
1118
1119

1120 Appendix 1: Information required for safety assessment when foods are or include
1121 organisms obtained through recombinant DNA techniques.
1122

1123 Appendix 2: Information required for safety assessment when foods and food
1124 additives are manufactured by use of living organisms obtained through
1125 recombinant DNA techniques.
1126 (<https://www.mhlw.go.jp/english/topics/food/3-3.html>)
1127

1128 Ladics G, Cressman R, Herman R, Privalle L, Song P, Ward J, McClain S, Bioinformatics and
1129 the allergy assessment of agricultural biotechnology products: industry practices and
1130 recommendations. *Reg.Toxicol. Pharmacol.*, 60, 46-53, 2011.
1131 <https://doi.org/10.1016/j.yrtph.2011.02.004>
1132
1133 Ladics G & Sewalt V Industrial microbial enzyme safety: what does the weight-of-evidence
1134 indicate? *Reg. Tox.Pharm.* 98, 151-154, 2018
1135
1136 NCBI <http://www.ncbi.nlm.nih.gov/>
1137
1138 OECD (!992) Safety considerations for biotechnology; elaboration of criteria and principles
1139 for good industrial large-scale practice (GILSP) [http://www.oecd.org/sti/emerging-](http://www.oecd.org/sti/emerging-tech/2375496.pdf)
1140 [tech/2375496.pdf](http://www.oecd.org/sti/emerging-tech/2375496.pdf)
1141
1142 Olempska-Beer Z, Merker R, Ditto M & DiNovi, M Food-processing enzymes from
1143 recombinant microorganisms – a review. *Reg Tox Pharmacol.* (2006) 45, 144-158
1144
1145 Pariza MW, Foster EM. Determining the safety of enzymes used in food processing. *J Food*
1146 *Prot.* (1983) 46 453-468.
1147
1148 Pariza MW, Johnson EA. Evaluating the safety of microbial enzyme preparations used in
1149 food processing: Update for a new century. *Regul Toxicol Pharmacol.* (2001) 33: 173-186
1150
1151 Pariza MW, Cook M. Determining the safety of enzymes used in animal feed. *Regul Toxicol*
1152 *Pharmacol.* (2010); 56: 332-342.
1153
1154 Sewalt V, Shanahan O, Gregg L, La Marta J, Carrillo R. The Generally Recognized as Safe
1155 (GRAS) Process for Industrial Microbial Enzymes. *Ind Biotechnol.* (2016); 12: 295-302.
1156
1157 Sewalt V, La Marta J, Shanahan O, Gregg L, Carrillo R. Letter to the editor regarding "GRAS
1158 from the ground up: Review of the Interim Pilot Program for GRAS notification" by Hanlon
1159 et al., 2017. *Food and Chemical Toxicol.* (2017); 107(Pt A): 520-521.
1160
1161 West-Barnette S & Srinivarsan JR, Regulatory Aspects of Food Ingredients in the United
1162 States: Focus on the Safety of Enzyme Preparations Used in Food. in *Adv. Food Sci Technol.*
1163 (2013) (eds: Visakh PM, Thomas S, Iturriaga LB and Ribotta PD) pp 201-226
1164
1165 WHO guidance for enzyme evaluation (2016, unpublished)
1166
1167 WHO/FAO 2001 Decision Tree Approach to the Evaluation of the Allergenicity of
1168 Genetically Modified Foods (<http://www.fao.org/docrep/007/y0820e/y0820e05.htm>)

1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214

Exhibit 1.

Outline of ILSI China Workshop , June 2018:

“In China, the criteria of safety assessment and approval pathway for food additives including food enzymes derived from GMMs have been discussed for years and still no clear clarification. All impacted food additives including enzymes are pending for approval since 2009.

It was clear that Ministry of Health and the Ministry of Agriculture (MOA) had discussed the matter, and industry started to make GMM dossier submissions in 2013 under the existing Agri-GMO guidelines, mainly for evaluating GMO crops. The MOA apparently received numerous GMM dossiers, including some for food enzymes, and reacted in 2014 by rejecting its responsibility for GMM oversight for food enzymes, and announcing it would no longer receive GMM dossiers for food enzymes.

As of June 2017, the NHFPC (National Health and Family Planning Commission; successor of MOH) and the MOA reached an agreement under which the MOA will serve a technical reviewer of a GMM dossier as part of the overall review and approval process by the NHFPC. Therefore, MOA tasked a technical expert committee to develop GMM evaluation guidance appropriate for food ingredients. Since August of 2017, industry has engaged with the committee in several workshops, resulting in a draft guidance that distinguishes 3 categories of food GMMs based on living GMMs level, which is similar to EFSA Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. MOA is conducting a technical review on the draft guidance.

Industry partners are focused on getting the MOA to move on approving the draft guidance covering 3 categories below:

- 1) Purified products made with GMMs, but living GMMs and inserted genes removed;
- 2) Composite products made with GMMs, but living GMMs removed;
- 3) Products containing living GMMs.

Based on the latest alignment between MOA and NHFPC, the door of the registration for the food enzymes produced from GMMs are expected to be re-opened soon. However, the door for many other food ingredients such as vitamins, amino acids, steviol glycosides and oligosaccharides (GOS and HMO) derived from GMMs, which are under Category 1 is still closed. Actually, the inserted GM genes and microorganisms are totally removed from the final products. Those food ingredients are chemically defined purified compounds and not evaluated as GM-crop process in general in the EU and US. GMM-derived food enzymes produced under containment do not contain the GMM used to produce them, hence they are not genetically modified organisms (GMOs), unlike Agri-GMO intended for deliberate release.

We hope that the workshop will be able for Chinese regulators and experts to clarify the different safety risks between GMMs derived products and GM crops, so the future safety assessment and approval pathway can to be straightforward and practical.”

1215 **Exhibit 2.**
1216 **IECG Charter**
1217

IECG charter

Final

Charter – International Enzyme Coordination Group

Background

Companies that manufacture, formulate and/or sell enzymes and enzyme products are organized in professional enzyme associations and advocacy groups based in various regions of the world.

These enzyme associations/advocacy groups have identified the need for a structured and continuous exchange of information and coordination of initiatives amongst themselves, in order to achieve stronger, common positions and better harmonization in safety, regulatory and technical matters.

As a result, these various global associations/advocacy groups have established the "International Enzyme Coordination Group", further referred to as the "IECG".

Mandate

The IECG itself does not act other than through the individual enzyme associations.

The aim of the IECG is to identify and seek consensus on relevant regulatory, legislative, safety and technical issues that are global or are expected to have an effect across regions, with the purpose to:

- Establish global standards for the safety and quality of enzyme products.
- Support each regional enzyme association with unified positions in order to maximize the interaction with the regional governmental authorities and to maintain a globally balanced governance.
- Promote coherence between activities and positions towards international standard setting bodies, such as Codex and JECFA.
- Stimulate global regulatory harmonization.
- Seek participation of other geographically distinct associations.

Composition of the IECG

The current enzyme associations and advocacy groups represented in the IECG are:

- Amfep – The Association of Manufacturers and Formulators of Enzyme Products – www.amfep.org
- E.A. – The Enzyme Technical Association – www.enzymeassociation.org
- JEA – Japanese Enzyme Association – http://j-enzyme.com/index_Eng.html
- ABIAM – Associação Brasileira da Indústria e Comércio de Ingredientes e Aditivos para Alimentos – www.abiam.com.br
- CERF – China Enzyme Regulatory Forum.

Other enzyme associations or advocacy groups that may develop in geographically distinct regions will be considered for IECG membership (e.g. advocacy groups in India, Latin American countries, Australia / New Zealand), provided that their charters are in compliance with competition laws.

April 4, 2017
DS:/ 92629959.1

p. 1/2

1218
1219

1220 *Annex 2. Definitions for Safe Food Enzyme Production Strain and Presumed Safe*
1221 **Progeny Strain (Class I Type iii)**

1222
1223 **A Safe Food Enzyme Production Strain** is a non-pathogenic, non-toxicogenic
1224 microbial strain with a demonstrated history of safe use in the manufacture of food enzymes.
1225 Evidence supporting this history of safe use includes knowledge of taxonomy, genetic
1226 background, toxicological testing, other aspects related to the safety of the strain, and
1227 commercial food use.

1228 **A Presumed Safe Progeny Strain** is developed from a safe food enzyme production
1229 strain through specific non-random modifications to its genome; the modifications must be
1230 thoroughly characterized, must not encode any harmful substances and not result in adverse
1231 effects. This concept also applies to multiple generations of progeny. Evidence supporting
1232 its safety includes knowledge of taxonomy, genetic background, and toxicological testing.

1233 **Annex 3. Information required for the safety assessment of enzyme preparation for use**
 1234 **in foods**

1235
 1236 Class I: Enzymes derived from sources which are considered safe for consumption and for
 1237 which toxicological evaluations are NOT normally required

1238 Type i: Enzymes obtained from edible tissues of plants or animals commonly used
 1239 as foods I(i).

1240 Type ii: Enzymes derived from micro-organisms that are traditionally accepted as
 1241 constituents of foods or are normally used in the preparation of foods I(ii).

1242 Type iii: Enzymes derived from a Safe Food Enzyme Production Strain or a
 1243 Presumed Safe Progeny Strain I(iii).

1244 Class II: Enzymes derived from sources which are NOT considered safe for consumption and
 1245 are not in any of the sub-categories listed above

1246

No.	Class/es	Information required	Details/ Rationale
Enzyme classification and description of active components of enzyme preparation			
1.	All	Name of enzyme(s)	e.g. Triacylglycerol lipase
2.	All	Systematic name(s) and number(s)	EC/IUBMB Number; CAS Number (where appropriate)
3.	All	Molecular weight(s)	As determined by SDS PAGE, gel filtration chromatography etc.
4.	All	Amino acid sequence(s)	Predicted and determined primary amino acid sequence
5.	All	Catalytic activity	All reactions catalyzed including any secondary activities, conditions under which catalysis occurs, e.g. pH, temperature)
6.	All	Historical use(s) in food-based applications	Evidence of commercial food use, including from the parent strain or other strains in the lineage

			e.g. as a processing aid in the manufacture of bakery products, pasta and noodles, in egg yolk and in oil degumming
7.	All	Use levels in food(s)	Express each use as Total Organic Solids (TOS) in mg/kg food
8.	All	Fate in final food(s)	Is the enzyme active, inactive or removed? How is the enzyme inactivated/ removed?
9.	All	Existing safety evaluations	Include any existing health-based guidance values (e.g., ADI)
Details about the Production Organism			
10.	All	Identity of the production organism	Identify genus, species, strain
11.	I (iii), II	Host/recipient organism	Identify genus, species
12.	I (iii), II	Donor/source of genetic material	e.g., identify source of genetic material by genus, species (native, modified or synthetic)
13.	I (iii), II	<p>Details of genetic modification:</p> <p>i. To host genome</p> <p>ii. Addition of rDNA (gene of interest from another microorganism) to host microorganism through mobile genetic elements</p>	<p>History of development of host strain (e.g. deletion of gene clusters that encode for aflatoxins, modifications that make host extracellular protease deficient or make it non-sporulating etc.), identification of genes removed/ added</p> <p>Donor/ source of genetic material, details on how the genetic element was designed and the identity of genes on the element, stability information, copy numbers, whether it integrates or does not integrate into host genome, etc.</p>

			Evidence that genetic material does not contain genes coding for virulence factors, protein toxins, or any enzymes that may be involved in the synthesis of mycotoxins
14.	I (iii), II	Genetic modification techniques	Site-directed mutagenesis, chemical mutagenesis, recombinant DNA technology, etc.
15.	I (iii), II	Description of intended and non-specific effects resulting from genetic modification and any changes carried out to prevent unwanted side reactions/ products	e.g., an intended effect may be increased yield; a non-specific effect may be activation of toxin production. Rectification measures may include genetic modifications, specific fermentation conditions etc.
16.	All	Deposit information (if applicable)	e.g., ATCC number

Production of Enzyme Concentrate and Preparation

17.	All	Detailed manufacturing process	<p>For enzymes in Class I(i) and Class I(ii), and Class II enzymes derived from plants and animals, manufacturing details are required.</p> <p>For enzymes in Class I(iii) and Class II produced by micro-organisms, include details describing controlled fermentation inputs and conditions, the steps taken to retain genetic modifications, and further processing, purification and concentration steps. Indicate how production strains are maintained under conditions that ensure the absence of genetic drift and when used in the production of enzyme preparations, indicate the methods and conditions that are applied to ensure consistency and reproducibility from batch to batch. Such conditions must ensure the absence of toxin production by the source organism and prevent the introduction of microorganisms that</p>
-----	-----	--------------------------------	---

			could be the source of toxic or other undesirable substances.
18.	All	Formulation ingredients	<p>Identify the carriers, diluents, excipients, supports and other additives and ingredients (including processing aids) used in the production, stabilization and application of enzyme preparations must be acceptable for food use.</p> <p>In order to distinguish the proportion of the enzyme preparation derived from the source material as opposed to that contributed by diluents and other additives and ingredients, individual specifications require a statement of percentage Total Organic Solids (TOS) which is defined as follows:</p> $\% \text{ TOS} = 100 - (A + W + D)$ <p>Where A = % ash, W = % water and D = % diluents and/or other additives and ingredients.</p> <p>TOS content is usually expressed in milligrams or micrograms TOS per kilogram body weight per day.</p>
Specifications & Data required for Enzyme Concentrates and Preparations			
19.	All	Description	Physical form of the enzyme preparation – liquid, semiliquid or dried product.
20.	All	Purity	<p>Impurities including elemental and microbiological impurities</p> <p>Analytical test methods, validation data, representative batch data (minimum of 5 batches) are required.</p>

21.	All	Enzyme characterization	Enzyme activity (including method of assay, activity unit definition), molecular weight determination for the enzyme and other specific identification techniques. A universally usable test method to define enzyme activity present in the preparation should be submitted Analytical test methods, validation data, representative batch data (minimum of 5 batches) are required.
22.	All	Analysis of at least five non-consecutive batches of the enzyme concentrate (for enzymes in Class II, at least one of which should have been used for toxicological testing)	e.g., TOS, enzyme activity, protein concentration, impurities, absence of antibiotic inactivating proteins. etc.
23.	All	Composition of at least five non-consecutive batches of the product(s) of commerce (enzyme preparation)	e.g., stabilizers, pH adjustment agents, carriers, diluents, preservatives, etc.
24.	I (iii), II	Information on carryover of allergens from the fermentation media to the enzyme concentrate	identification of major food allergens in media components
25.	I (iii), II	Evidence for absence of recombinant DNA and production organisms in the enzyme concentrate	
Assessment of Potential Allergenicity of the Enzyme			
26.	I (iii), II	Comparison of the amino acid sequence of the enzyme to known allergens	<i>In silico</i> comparison of primary amino acid structure with allergen databases to confirm the absence of sequence homology with known allergenic proteins. <ul style="list-style-type: none"> i. Sequence homology (35% of a sliding window of 80 amino acids) ii. Sequence identity in contiguous stretches of 8 amino acids within the enzyme sequence

			All the information resulting from the sequence homology comparison between an expressed enzyme and known allergens should be reported. If any of the identity scores equals or exceeds 35%, this is considered to indicate significant homology and needs to be scientifically considered in the context of a safety assessment for enzymes in food.
27.	I (iii), II	Proteolysis resistance/ digestibility of the enzyme	e.g., Simulated gastric fluid (SGF) studies, etc.
Toxicology			
28.	II	Results of toxicological testing of the enzyme concentrate.	It is necessary to conduct toxicological studies in order to establish an ADI: (a) 90-day oral toxicity test in a rodent species; (b) Two short-term genotoxicity tests (mutagenicity and clastogenicity) 1. A test for gene-mutations in bacteria, 2. A test for chromosomal aberrations (preferably in vitro).
29.	I (iii), II	Bioinformatic analysis of the amino acid sequence for potential matches with known toxins	Explanation of the analysis and interpretation should be provided
Dietary Exposure Assessment			
30.	II	Estimate of dietary exposure to the enzyme preparation calculated on the basis of the total organic solids (TOS). Separate dietary exposure situations may need to be considered with respect to the	Express the dietary exposure as mg TOS/kg bw per day; provide an explanation of the methodology used to derive the estimated dietary exposure

		<p>enzymes described in Classes I (iii) and II, depending on whether they are:</p> <p>a) enzyme preparations added directly to food and not removed;</p> <p>b) enzyme preparations added to food but removed from the final product according to Good Manufacturing Practice (GMP); or</p> <p>c) immobilized enzyme preparations that are in contact with food only during processing.</p>	
31		Additional information and comments	Additional items considered helpful in the safety assessment

1247

1248 *Annex 4. Terms and definitions*

1249

Terms	Definitions
Source/Donor Organism	The animal, plant or microorganism that provides the genetic material used to modify the Host/Recipient organism that will express the enzyme or enzymes of interest. It is typically described by genus, species and strain.
Host/Recipient Organism	The animal, plant or microorganism that receives the genetic material from the Source/Donor organism. It is typically described by genus, species and strain.
Production Organism/Strain	The animal, plant or microorganism that is used to express the enzyme or enzymes of interest. It is typically described by genus, species and strain.
Enzyme	The identity of the specific biologically active protein used to catalyze the reaction of interest. It is typically characterized by a specific amino acid sequence and described using EC/IUBMB nomenclature.
Enzyme concentrate	The product after manufacturing (typically from fermentation) and before formulation of the enzyme preparation; it contains the enzyme of interest along with other components from the manufacturing process and its composition is expressed in Total Organic Solids (TOS). This is the material typically used for toxicological studies.
Formulation ingredients	Food-grade materials, e. g. stabilizers, pH adjustment agents, carriers, diluents, preservatives, etc., that are added to the enzyme concentrate to make the enzyme preparation.
Enzyme preparation	Consists of the enzyme concentrate and formulation ingredients; it represents the article of commerce used in food production.

1250

1251 *Annex 5. List of experts*

1252

1253 **Members of the JECFA Expert Working Group established to consider the evaluation**
1254 **of enzyme preparations used in the manufacture of foods**

1255 • Maria Beatriz de Abreu GLORIA, Brazil

1256 • Daniel FOLMER, USA

1257 • G. J. Benoit GNONLONFIN, Nigeria

1258 • Suzanne JEURISSEN, The Netherlands

1259 • Kristie LAURVICK, USA

1260 • Madduri V. RAO, India

1261 • Joel ROTSTEIN, Canada

1262 • Mohammad SHOJAEI, IRAN

1263 • Jannavi SRINIVASAN, USA

1264 • Atsuko TADA, Japan

1265 • Imad TOUFEILI, Lebanon

1266 • Yongning WU, China

1267

1268 JECFA Secretariat

1269 • Richard CANTRILL, Canada

1270 • Markus LIPP, FAO, Italy

1271 • Utz MUELLER, Australia

1272 • Keya MUKHERJEE, FAO, Italy

1273 • Kim PETERSEN, WHO, Switzerland

1274 • Zhe ZHANG, FAO, Italy

1275 Codex Secretariat

1276 • Lingping ZHANG, FAO, Italy